Please Wait.....
Report
Cervical Cancer Therapeutics Market - Epidemiology & Pipeline Analysis 2022-2027
Market Report I 2022-06-27 I 191 Pages I Arizton Advisory & Intelligence
The Cervical Cancer Therapeutics market is expected to grow at a CAGR of 4.14% during 2021-2027.
Cervical cancer is a disease in which malignant cells are formed in the tissues of the cervix, the lower part of the uterus that connects to the vagina. Human papillomavirus (HPV) infection is the major risk factor for cervical cancer.
According to Arizton's estimates, the diagnosed incident cases of cervical cancer were high in China, followed by the U.S. and Japan in 2020. The increasing prevalence of HIV (Human Immunodeficiency Virus) in women is driving the growth of the cervical cancer drugs market. Women with HIV positive have a greater risk of cervical cancer than the general population. Nearly 18 million women have tested HIV positive globally; HIV weakens the immune system, which increases the likelihood of cervical cancer. Surgery is the standard of care for the treatment of early-stage, while chemoradiation is the most common treatment modality for locally advanced disease. In the U.S., the approvals of Keytruda as first-line therapy and Tivdak as second-line therapy in 2021 wholly altered the treatment paradigm for recurrent and distally metastatic disease. Before the approval of Keytruda in the first line, patients received chemotherapy with Avastin, which remains the treatment of choice outside the U.S.
MARKET TRENDS & DRIVERS
Early Detection of Disease: More than 90% of cervical malignancies occur due to HPV infection (human papillomavirus), which can be diagnosed through smear screening. The Pap smear test, the most effective tool for diagnosing HPV in the early stage, is the most revenue-generating segment.
Increasing Prevalence of Cervical cancer: The market study has been witnessing considerable growth, attributed to the increasing prevalence of cervical cancer among women worldwide. In 2018, an estimated 570 000 women were diagnosed with cervical cancer worldwide, and about 311 000 women died due to improper detection at the early stages of the disease.
MARKET SEGMENTATION
Drug Class: Chemotherapeutic drugs are expected to dominate the global cervical cancer therapeutics market. However, the targeted therapies are expected to be the fastest-growing segment during the forecast period. Recently approved biological drugs such as Keytruda (pembrolizumab) and Tivdak (tisotumab-vedotin-tftv) are expected to drive the targeted therapies segment during the forecast period.
Histology type: Among the histology type, Squamous cell Carcinoma is expected to account for a significant share of the global cervical cancer therapeutics market. However, Adenocarcinoma is the fastest-growing segment during the forecast period due to its aggressive nature.
Age Group: Among the Age group, women aged 50 years are expected to account for a significant portion of the global cervical cancer therapeutics market share. However, women between the age of 30 - 49 years are expected to be the fastest-growing segment during the forecast period.
Distribution type: Among the distribution type, Retail & Specialty pharmacy services are expected to dominate the cervical cancer therapeutics market. According to the National Comprehensive Cancer Network Specialty Pharmacy Task Force, more than 80% of managed care organizations reported contracting with specialty pharmacy providers for their oncology business, and 51.4% reported using a single, preferred specialty provider for all limited-distribution drugs.
Segmentation by Drug Class
- Chemotherapy
- Targeted therapy
Segmentation by Histology Type
- Squamous cell carcinoma
- Adenocarcinoma
- Aden squamous
Segmentation by Distribution Channel
- Hospital & Clinics
- Retail & Specialty Pharmacies
Segmentation by Age Group
- Below 29 years
- 30-49 years
- 50+ years
Geography: The U.S. dominates the cervical cancer therapeutics market due to the rise in the healthcare affordability in the U.S., rise in the knowledge and rise in the awareness amongst the people, and rises in the technological advancement in this region. However, China is expected to grow faster with a high CAGR in the cervical cancer drug market due to a rise in healthcare access and quality, increased awareness about disease management, and rising healthcare expenditure. The trend of biosimilars in emerging markets, such as China and Japan, could potentially alter the therapeutic landscape in this region.
Segmentation by Region
- North America
o S.
- Europe
o France
o Germany
o Italy
o UK
o Spain
- APAC
o China
o Japan
Cervical Cancer Therapeutics: Pipeline Scenario The cervical cancer portfolio contains a total of 169+ assets that are in various phases of development. Most industry-sponsored drugs in active clinical development for cervical cancer are in the Phase II stage. The distribution of the pipeline drugs across Phase I-IV is dominated by Phase II (35.5%), followed by Phase I (31.36%), and then Phase III (7.10%).
Cervical Cancer Therapeutics: Clinical Trials Scenario
The clinical trial portfolio contains 282+ trials in various phases of development. The majority of the industry-sponsored drugs in active clinical development for cervical cancer are in Phase II, with three drugs in the NDA/BLA stage. The distribution of clinical trials across Phase I-IV indicates that the vast majority of problems for cervical cancer have been in the early and mid-phases of development, with 94% of issues in Phase I-II and only 6% in Phase III-IV. The U.S. has a substantial lead in the number of cervical cancer clinical trials globally. The U.K. leads the primary European markets, while China has the top spot in Asia. Based on the efficacy demonstrated with pembrolizumab and the significant role of PD-L1 in cervical cancer, various anti-P.D.-(L)1 agents are currently under investigation as first-line therapies in cervical cancer. For instance, Atezolizumab and prolgolimab (BCD-100) combined with chemotherapy with or without bevacizumab and pembrolizumab with chemoradiotherapy are ongoing. In addition, several trials are examining novel combinations in this space.
COMPETITIVE SCENARIO
The cervical cancer treatment market is dominated by many companies offering generic drugs and particular pharma/biotech companies offering patented/commercial drugs for treating cervical cancer. The U.S. Food and Drug Administration (FDA) approved the antiangiogenic agent bevacizumab (Avastin) to treat persistent, recurrent, or metastatic cervical cancer in 2014. This marked the arrival of biologics in this treatment landscape. Avastin was approved in Europe and Japan in 2015 and 2016, respectively. The FDA approved Keytruda (pembrolizumab) in 2018 and Tivdak (tisotumab-vedotin-tftv) in 2021 to treat cervical cancer. Although generic products continue to capture significant market share, the arrival of biologics and other targeted therapies indicates a paradigm shift in this therapeutic space through the forecast period.
Key Vendors:
- Seagen Inc
- Merck
- Roche
- Pfizer
- Sanofi/Regeneron
- Lee's Pharma/Sorrenti
- Akesobio
- HengRui Medicine Co., Ltd
- Henlius Biotech
- Biocad
- Advenchen Laboratories
- EXELIXIS
- Novertis
- GSK
- Zeria Pharmaceuticals
Other Prominent Vendors
- Innovent Biologics
- Clovis Oncology
- IOVANCE Biotherapeutics
- Genor Biopharma Co., LTD
- Agenusbio
- Qilu Pharmaceutical
- Astrazeneca
- Puma Biotechnology
- Genmab
- Takeda
- Incyte Corp
- BioAtla, Inc.
- Helsinn Healthcare SA
- Qilu Pharmaceutical
- BeiGene
REPORT COVERAGE
- Detailed overview of cervical cancer, including disease definition, classification, diagnosis, and treatment pattern.
- Overview of the global trends of cervical cancer in the eight major markets (8MM)
- Historical, current, and projected patient pool of cervical cancer in the eight primary markets (8MM) for 2018-2027.
- Age group, Histology, Drug Class, and Drug Distribution type segmentation of cervical cancer in the eight major markets (8MM)
- Market Share of the market players, Company profiles, product specifications, and competitive landscape.
- Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints.
- Detailed overview of therapeutics pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and geography type for cervical cancer across all clinical stages.
- Coverage of dormant and discontinued pipelines projects along with the reasons across cervical cancer
- Coverage of significant milestones (products approvals/launch timelines, clinical trial result publication, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the cervical cancer space.
KEY QUESTIONS ANSWERED
1. WHAT IS THE MARKET SIZE OF THE CERVICAL CANCER THERAPEUTICS MARKET?
2. WHAT IS THE GROWTH RATE OF THE CERVICAL CANCER THERAPEUTICS MARKET?
3. WHO ARE THE KEY PLAYERS IN THE CERVICAL CANCER THERAPEUTICS MARKET?
4. WHAT ARE THE SEGMENTS COVERED IN THE CERVICAL CANCER THERAPEUTICS MARKET?
CHAPTER - 1: CERVICAL CANCER OVERVIEW
- Cervical Cancer - An Overview
CHAPTER - 2: CERVICAL CANCER EPIDEMIOLOGY & OVERVIEW
- 8MM: Historic & Projected Volume of incidence & prevalence of Cervical cancer
- 8MM: Comparative analysis of incidence & prevalence of Cervical cancer
- 8MM: Historic & Projected Volume of incidence of Cervical cancer cases by Age Group
- 8MM: Comparative analysis of incidence of Cervical cancer cases by Age Group
- US: Historic & Projected Volume of incidence & prevalence of Cervical cancer
- US: Comparative analysis of incidence & prevalence of Cervical cancer
- US: Historic & Projected Volume of incidence of Cervical cancer cases by Age Group
- US: Comparative analysis of incidence of Cervical cancer cases by Age Group
- China: Historic & Projected Volume of incidence & prevalence of Cervical cancer
- China: Comparative analysis of incidence & prevalence of Cervical cancer
- China: Historic & Projected Volume of incidence of Cervical cancer cases by Age Group
- China: Comparative analysis of incidence of Cervical cancer cases by Age Group
- Japan: Historic & Projected Volume of incidence & prevalence of Cervical cancer
- Japan: Comparative analysis of incidence & prevalence of Cervical cancer
- Japan: Historic & Projected Volume of incidence of Cervical cancer cases by Age Group
- Japan: Comparative analysis of incidence of Cervical cancer cases by Age Group
- Germany: Historic & Projected Volume of incidence & prevalence of Cervical cancer
- Germany: Comparative analysis of incidence & prevalence of Cervical cancer
- Germany: Historic & Projected Volume of incidence of Cervical cancer cases by Age Group
- Germany: Comparative analysis of incidence of Cervical cancer cases by Age Group
- UK: Historic & Projected Volume of incidence & prevalence of Cervical cancer
- UK: Comparative analysis of incidence & prevalence of Cervical cancer
- UK: Historic & Projected Volume of incidence of Cervical cancer cases by Age Group
- UK: Comparative analysis of incidence of Cervical cancer cases by Age Group
- France: Historic & Projected Volume of incidence & prevalence of Cervical cancer
- France: Comparative analysis of incidence & prevalence of Cervical cancer
- France: Historic & Projected Volume of incidence of Cervical cancer cases by Age Group
- France: Comparative analysis of incidence of Cervical cancer cases by Age Group
- Italy: Historic & Projected Volume of incidence & prevalence of Cervical cancer
- Italy: Comparative analysis of incidence & prevalence of Cervical cancer
- Italy: Historic & Projected Volume of incidence of Cervical cancer cases by Age Group
- Italy: Comparative analysis of incidence of Cervical cancer cases by Age Group
- Spain: Historic & Projected Volume of incidence & prevalence of Cervical cancer
- Spain: Comparative analysis of incidence & prevalence of Cervical cancer
- Spain: Historic & Projected Volume of incidence of Cervical cancer cases by Age Group
- Spain: Comparative analysis of incidence of Cervical cancer cases by Age Group
CHAPTER - 3: CERVICAL CANCER MARKET SIZE & OVERVIEW
- 8MM: Historic & Projected Revenue of Cervical Cancer
- 8MM: Historic & Projected Revenue of Cervical Cancer Snapshot
- 8MM: Historic & Projected Revenue Segmentation by Age Group, Histology type, Drug Class & Distribution type
- US: Historic & Projected Revenue of Cervical Cancer
- US: Historic & Projected Revenue of Cervical Cancer Snapshot
- US: Historic & Projected Revenue Segmentation by Age Group, Histology type, Drug Class & Distribution type
- China: Historic & Projected Revenue of Cervical Cancer
- China: Historic & Projected Revenue of Cervical Cancer Snapshot
- China: Historic & Projected Revenue Segmentation by Age Group, Histology type, Drug Class & Distribution type
- Japan: Historic & Projected Revenue of Cervical Cancer
- Japan: Historic & Projected Revenue of Cervical Cancer Snapshot
- Japan: Historic & Projected Revenue Segmentation by Age Group, Histology type, Drug Class & Distribution type
- Germany: Historic & Projected Revenue of Cervical Cancer
- Germany: Historic & Projected Revenue of Cervical Cancer Snapshot
- Germany: Historic & Projected Revenue Segmentation by Age Group, Histology type, Drug Class & Distribution type
- UK: Historic & Projected Revenue of Cervical Cancer
- UK: Historic & Projected Revenue of Cervical Cancer Snapshot
- UK: Historic & Projected Revenue Segmentation by Age Group, Histology type, Drug Class & Distribution type
- France: Historic & Projected Revenue of Cervical Cancer
- France: Historic & Projected Revenue of Cervical Cancer Snapshot
- France: Historic & Projected Revenue Segmentation by Age Group, Histology type, Drug Class & Distribution type
- Italy: Historic & Projected Revenue of Cervical Cancer
- Italy: Historic & Projected Revenue of Cervical Cancer Snapshot
- Italy: Historic & Projected Revenue Segmentation by Age Group, Histology type, Drug Class & Distribution type
- Spain: Historic & Projected Revenue of Cervical Cancer
- Spain: Historic & Projected Revenue of Cervical Cancer Snapshot
- Spain: Historic & Projected Revenue Segmentation by Age Group, Histology type, Drug Class & Distribution type
CHAPTER - 4: CERVICAL CANCER MARKETED DRUGS OVERVIEW
- Cervical Cancer Marketed Drugs - An Overview
- Cervical Cancer Marketed Drugs - Summary
CHAPTER - 5: CERVICAL CANCER PIPELINE DRUGS OVERVIEW
- Cervical Cancer Pipeline Drugs - An Overview
- Cervical Cancer Pipeline Drugs - Snapshot
- Cervical Cancer Pipeline Drugs Overview & Snapshot - By Disease type
- Cervical Cancer Pipeline Drugs Overview & Snapshot - By Development Phase
- Cervical Cancer Pipeline Drugs Overview & Snapshot - By Route of Administration
- Cervical Cancer Pipeline Drugs Overview & Snapshot - By Mechanism of Action
- Cervical Cancer Pipeline Drugs Overview & Snapshot - By Molecule type
- Cervical Cancer Pipeline Drugs Overview & Snapshot - By Geography type
CHAPTER - 6: CERVICAL CANCER CLINICAL TRIALS OVERVIEW
- Cervical Cancer Clinical Trials Overview Snapshot
- Cervical Cancer Clinical Trials Overview - By Recruitment Status
- Cervical Cancer Clinical Trials Overview - By Product type
- Cervical Cancer Clinical Trials Overview - By Route of Administration
- Cervical Cancer Clinical Trials Overview - By Molecule type
- Cervical Cancer Clinical Trials Overview - By Geography type
CHAPTER - 7: CERVICAL CANCER MARKET DYNAMICS
- Cervical Cancer Treatment Market Drivers
- Cervical Cancer Treatment Market Constraints
- Cervical Cancer Treatment Market Trends
CHAPTER - 8: CERVICAL CANCER COMPETITIVE LANDSCAPE
- Cervical Cancer Competitive Landscape - Marketed Drugs
- Key Company Profiles
- Competitive Scenario of Cervical Cancer Treatment Market
- Other Prominent Company Profiles
- Key Company Overviews
- Cervical Cancer Competitive Landscape - Pipeline Drugs
- Key Emerging Company Profiles
- Key Emerging Company Overviews
- Other Prominent Company Profiles
CHAPTER - 9: CERVICAL CANCER MISCELLANEOUS
- Key Tentative Drug Approvals Timeline
- Key Regulatory Designations
- Key Milestones
- Deals & Collaborations
- Potential Trial Head-to-Head Comparison
- Inactive/Discontinued/Dormant Products
- Unmet needs & Strategic Recommendations
CHAPTER - 10: APPENDIX
- About Arizton
- Research Methodology
- List of Abbreviations
LIST OF EXHIBITS
Exhibit 1: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN 8 MAJOR MARKETS (2018 - 2027)
Exhibit 2: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN 8 MAJOR MARKETS (2018 - 2020)
Exhibit 3: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN 8 MAJOR MARKETS (2021 - 2027)
Exhibit 4: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN 8 MAJOR MARKETS (2018 - 2027)
Exhibit 5: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN 8 MAJOR MARKETS (2018 - 2020)
Exhibit 6: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN 8 MAJOR MARKETS (2020 - 2021)
Exhibit 7: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN US (2018 - 2027)
Exhibit 8: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN US (2018 - 2020)
Exhibit 9: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN US (2021 - 2027)
Exhibit 10: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN US (2018 - 2027)
Exhibit 11: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN US (2018 - 2020)
Exhibit 12: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN US (2020 - 2021)
Exhibit 13: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN CHINA (2018 - 2027)
Exhibit 14: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN CHINA (2018 - 2020)
Exhibit 15: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN CHINA (2021 - 2027)
Exhibit 16: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN CHINA (2018 - 2027)
Exhibit 17: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN CHINA (2018 - 2020)
Exhibit 18: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN CHINA (2020 - 2021)
Exhibit 19: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN JAPAN (2018 - 2027)
Exhibit 20: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN JAPAN (2018 - 2020)
Exhibit 21: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN JAPAN (2021 - 2027)
Exhibit 22: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN JAPAN (2018 - 2027)
Exhibit 23: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN JAPAN (2018 - 2020)
Exhibit 24: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN JAPAN (2020 - 2021)
Exhibit 25: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN GERMANY (2018 - 2027)
Exhibit 26: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN GERMANY (2018 - 2020)
Exhibit 27: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN GERMANY (2021 - 2027)
Exhibit 28: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN GERMANY (2018 - 2027)
Exhibit 29: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN GERMANY (2018 - 2020)
Exhibit 30: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN GERMANY (2020 - 2021)
Exhibit 31: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN UK (2018 - 2027)
Exhibit 32: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN UK (2018 - 2020)
Exhibit 33: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN UK (2021 - 2027)
Exhibit 34: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN UK (2018 - 2027)
Exhibit 35: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN UK (2018 - 2020)
Exhibit 36: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN UK (2020 - 2021)
Exhibit 37: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN FRANCE (2018 - 2027)
Exhibit 38: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN FRANCE (2018 - 2020)
Exhibit 39: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN FRANCE (2021 - 2027)
Exhibit 40: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN FRANCE (2018 - 2027)
Exhibit 41: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN FRANCE (2018 - 2020)
Exhibit 42: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN FRANCE (2020 - 2021)
Exhibit 43: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN ITALY (2018 - 2027)
Exhibit 44: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN ITALY (2018 - 2020)
Exhibit 45: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN ITALY (2021 - 2027)
Exhibit 46: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN ITALY (2018 - 2027)
Exhibit 47: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN ITALY (2018 - 2020)
Exhibit 48: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN ITALY (2020 - 2021)
Exhibit 49: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN SPAIN (2018 - 2027)
Exhibit 50: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN SPAIN (2018 - 2020)
Exhibit 51: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN SPAIN (2021 - 2027)
Exhibit 52: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN SPAIN (2018 - 2027)
Exhibit 53: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN SPAIN (2018 - 2020)
Exhibit 54: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN SPAIN (2021 - 2027)
Exhibit 55: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET IN 8 MAJOR MARKETS (2021 - 2027)
Exhibit 56: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET SNAPSHOT IN 8 MAJOR MARKETS ( 2018 - 2020)
Exhibit 57: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY AGE GROUP IN 8 MAJOR MARKETS (2021 - 2027)
Exhibit 58: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DRUG CLASS IN 8 MAJOR MARKETS (2021 - 2027)
Exhibit 59: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET HISTOLOGY IN 8 MAJOR MARKETS (2021 - 2027)
Exhibit 60: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DISTRIBUTION TYPE IN 8 MAJOR MARKETS (2021 - 2027)
Exhibit 61: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET IN US (2018 - 2027)
Exhibit 62: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET SNAPSHOT IN US (2018 - 2020)
Exhibit 63: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY AGE GROUP IN US (2021 - 2027)
Exhibit 64: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DRUG CLASS IN US (2021 - 2027)
Exhibit 65: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET HISTOLOGY IN US (2021 - 2027)
Exhibit 66: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DISTRIBUTION TYPE IN US (2021 - 2027)
Exhibit 67: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET IN CHINA (2018 - 2027)
Exhibit 68: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET SNAPSHOT IN CHINA (2018 - 2020)
Exhibit 69: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY AGE GROUP IN CHINA (2021 - 2027)
Exhibit 70: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DRUG CLASS IN CHINA (2021 - 2027)
Exhibit 71: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET HISTOLOGY IN CHINA (2021 - 2027)
Exhibit 72: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DISTRIBUTION TYPE IN CHINA (2021 - 2027)
Exhibit 73: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET IN JAPAN (2018 - 2027)
Exhibit 74: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET SNAPSHOT IN JAPAN (2018 - 2020)
Exhibit 75: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY AGE GROUP IN JAPAN (2021 - 2027)
Exhibit 76: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DRUG CLASS IN JAPAN (2021 - 2027)
Exhibit 77: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET HISTOLOGY IN JAPAN (2021 - 2027)
Exhibit 78: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DISTRIBUTION TYPE IN JAPAN (2021 - 2027)
Exhibit 79: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET IN GERMANY (2018 - 2027)
Exhibit 80: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET SNAPSHOT IN GERMANY (2018 - 2020)
Exhibit 81: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY AGE GROUP IN GERMANY (2021 - 2027)
Exhibit 82: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DRUG CLASS IN GERMANY (2021 - 2027)
Exhibit 83: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET HISTOLOGY IN GERMANY (2021 - 2027)
Exhibit 84: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DISTRIBUTION TYPE IN GERMANY (2021 - 2027)
Exhibit 85: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET IN UK (2018 - 2027)
Exhibit 86: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET SNAPSHOT IN UK (2018 - 2020)
Exhibit 87: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY AGE GROUP IN UK (2021 - 2027)
Exhibit 88: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DRUG CLASS IN UK (2021 - 2027)
Exhibit 89: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET HISTOLOGY IN UK (2021 - 2027)
Exhibit 90: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DISTRIBUTION TYPE IN UK (2021 - 2027)
Exhibit 91: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET IN FRANCE (2018 - 2027)
Exhibit 92: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET SNAPSHOT IN FRANCE (2018 - 2020)
Exhibit 93: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY AGE GROUP IN FRANCE (2021 - 2027)
Exhibit 94: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DRUG CLASS IN FRANCE (2021 - 2027)
Exhibit 95: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET HISTOLOGY IN FRANCE (2021 - 2027)
Exhibit 96: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DISTRIBUTION TYPE IN FRANCE (2021 - 2027)
Exhibit 97: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET IN ITALY (2018 - 2027)
Exhibit 98: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET SNAPSHOT IN ITALY (2018 - 2020)
Exhibit 99: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY AGE GROUP IN ITALY (2021 - 2027)
Exhibit 100: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DRUG CLASS IN ITALY (2021 - 2027)
Exhibit 101: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET HISTOLOGY IN ITALY (2021 - 2027)
Exhibit 102: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DISTRIBUTION TYPE IN ITALY (2021 - 2027)
Exhibit 103: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET IN SPAIN (2018 - 2027)
Exhibit 104: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET SNAPSHOT IN SPAIN (2018 - 2020)
Exhibit 105: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY AGE GROUP IN SPAIN (2021 - 2027)
Exhibit 106: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DRUG CLASS IN SPAIN (2021 - 2027)
Exhibit 107: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET HISTOLOGY IN SPAIN (2021 - 2027)
Exhibit 108: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DISTRIBUTION TYPE IN SPAIN (2021 - 2027)
Exhibit 109: MARKETED DRUGS OVERVIEW IN CERVICAL CANCER TREATMENT MARKET
Exhibit 110: MARKETED DRUGS OVERVIEW SNAPSHOT IN CERVICAL CANCER TREATMENT
Exhibit 111: PIPELINE DRUGS OVERVIEW IN CERVICAL CANCER TREATMENT MARKET
Exhibit 112: CERVICAL CANCER PIPELINE DRUGS OVERVIEW BY DISEASE TYPE
Exhibit 113: CERVICAL CANCER PIPELINE DRUGS OVERVIEW BY DEVELOPMENT PHASE
Exhibit 114: CERVICAL CANCER PIPELINE DRUGS OVERVIEW BY ROUTE OF ADMINISTRATION
Exhibit 115: CERVICAL CANCER PIPELINE DRUGS OVERVIEW BY MECHANISM OF ACTION
Exhibit 116: CERVICAL CANCER PIPELINE DRUGS OVERVIEW BY MOLECULE TYPE
Exhibit 117: CERVICAL CANCER PIPELINE DRUGS OVERVIEW BY GEOGRAPHY TYPE
Exhibit 118: CERVICAL CANCER CLINICAL TRIAL ANALYSIS SNAPSHOT
Exhibit 119: CERVICAL CANCER CLINICAL TRIAL ANALYSIS SNAPSHOT BY RECRUITMENT STATUS
Exhibit 120: CERVICAL CANCER CLINICAL TRIAL ANALYSIS SNAPSHOT BY PRODUCT TYPE
Exhibit 121: CERVICAL CANCER CLINICAL TRIAL ANALYSIS SNAPSHOT BY ROUTE OF ADMINISTRATION
Exhibit 122: CERVICAL CANCER CLINICAL TRIAL ANALYSIS SNAPSHOT BY MOLECULE TYPE
Exhibit 123: CERVICAL CANCER CLINICAL TRIAL ANALYSIS SNAPSHOT BY GEOGRAPHY TYPE
Exhibit 124: COMPETITIVE ASSESSMENT OF CERVICAL CANCER TREATMENT MARKET
LIST OF TABLES
Table 1: KEY MARKET DRIVERS IN CERVICAL CANCER TREATMENT MARKET
Table 2: KEY MARKET CONSTRAINTS IN CERVICAL CANCER TREATMENT MARKET
Table 3: KEY MARKET TRENDS IN CERVICAL CANCER TREATMENT MARKET
Table 4: KEY TENTATIVE TIMELINE APPROVALS OF PIPELINE DRUHS IN CERVICAL CANCER
Table 5: KEY REGULATORY DESIGNATIONS OF PIPELINE DRUHS IN CERVICAL CANCER
Table 6: KEY MILESTONES IN CERVICAL CANCER TREATMENT MARKET
Table 7: KEY DEALS & COLLABORATIONS IN CERVICAL CANCER TREATMENT MARKET
Table 8: KEY POTENTIAL TRIAL COMPARISONS IN CERVICAL CANCER
Table 9: KEY INACTIVE/DISCONTINUED PRODUCTS IN CERVICAL CANCER TREATMENT
Table 10: KEY UNMET NEEDS & STRATEGIC RECOMMENDATIONS IN CERVICAL CANCER TREATMENT
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security